Early relapse prediction after allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia (ALL) using lineage-specific chimerism analysis
© 2022 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd..
Relapse is a major cause of treatment failure after hematopoietic stem cell transplantation (HSCT) for acute leukemia. Here, we report a monocentric retrospective study of all HSCTs for B cell acute lymphoblastic leukemia (ALL) performed during the years 2005-2021 (n = 138, including 51 children), aiming to identify the optimal use of lineage-specific recipient-donor chimerism analysis for prediction of relapse. In adults, relapse was associated with increased recipient chimerism in CD3+ bone marrow cells sampled at least 30 days before a relapse. Relapse could be predicted with a sensitivity of 73% and a specificity of 83%. Results were similar for children but with a higher recipient chimerism cutoff. Additionally, adults that had at least one chimerism value <0.12% in CD3+ peripheral blood cells within the first 60 days after HSCT had 89% probability of being relapse-free after 2-years compared to 64%. Results were similar for children but again necessitating a higher chimerism cutoff. These results suggest that high-sensitive lineage-specific chimerism analysis can be used for (1) early ALL relapse prediction by longitudinal chimerism monitoring in CD3+ bone marrow cells and (2) relapse risk stratification by analyzing CD3+ blood cells early post-HSCT.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:3 |
|---|---|
| Enthalten in: |
EJHaem - 3(2022), 4 vom: 24. Nov., Seite 1277-1286 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lindahl, Hannes [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acute leukemia |
|---|
| Anmerkungen: |
Date Revised 06.12.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1002/jha2.568 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM349803609 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM349803609 | ||
| 003 | DE-627 | ||
| 005 | 20231226043508.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/jha2.568 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1165.xml |
| 035 | |a (DE-627)NLM349803609 | ||
| 035 | |a (NLM)36467849 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lindahl, Hannes |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Early relapse prediction after allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia (ALL) using lineage-specific chimerism analysis |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 06.12.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2022 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd. | ||
| 520 | |a Relapse is a major cause of treatment failure after hematopoietic stem cell transplantation (HSCT) for acute leukemia. Here, we report a monocentric retrospective study of all HSCTs for B cell acute lymphoblastic leukemia (ALL) performed during the years 2005-2021 (n = 138, including 51 children), aiming to identify the optimal use of lineage-specific recipient-donor chimerism analysis for prediction of relapse. In adults, relapse was associated with increased recipient chimerism in CD3+ bone marrow cells sampled at least 30 days before a relapse. Relapse could be predicted with a sensitivity of 73% and a specificity of 83%. Results were similar for children but with a higher recipient chimerism cutoff. Additionally, adults that had at least one chimerism value <0.12% in CD3+ peripheral blood cells within the first 60 days after HSCT had 89% probability of being relapse-free after 2-years compared to 64%. Results were similar for children but again necessitating a higher chimerism cutoff. These results suggest that high-sensitive lineage-specific chimerism analysis can be used for (1) early ALL relapse prediction by longitudinal chimerism monitoring in CD3+ bone marrow cells and (2) relapse risk stratification by analyzing CD3+ blood cells early post-HSCT | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a acute leukemia | |
| 650 | 4 | |a chimerism analysis | |
| 650 | 4 | |a relapse prediction | |
| 650 | 4 | |a stem cell transplantation | |
| 700 | 1 | |a Valentini, Davide |e verfasserin |4 aut | |
| 700 | 1 | |a Vonlanthen, Sofie |e verfasserin |4 aut | |
| 700 | 1 | |a Sundin, Mikael |e verfasserin |4 aut | |
| 700 | 1 | |a Björklund, Andreas T |e verfasserin |4 aut | |
| 700 | 1 | |a Mielke, Stephan |e verfasserin |4 aut | |
| 700 | 1 | |a Hauzenberger, Dan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t EJHaem |d 2020 |g 3(2022), 4 vom: 24. Nov., Seite 1277-1286 |w (DE-627)NLM314118454 |x 2688-6146 |7 nnns |
| 773 | 1 | 8 | |g volume:3 |g year:2022 |g number:4 |g day:24 |g month:11 |g pages:1277-1286 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/jha2.568 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 3 |j 2022 |e 4 |b 24 |c 11 |h 1277-1286 | ||